Stanford Neurosciences Institute
Showing 1-10 of 279 Results
Gregory W. Albers, MD
The Coyote Foundation Professor and Professor, by courtesy, of Neurosurgery at the Stanford University Medical Center
Current Research and Scholarly Interests Our group's research focus is the acute treatment and prevention of cerebrovascular disorders. Our primary interest is the use of advanced imaging techniques to expand the treatment window for ischemic stroke. We are also conducting clinical studies of both neuroprotective and thrombolytic strategies for the treatment of acute stroke and investigating new antithrombotic strategies for stroke prevention.
Professor of Neurology at the Stanford University Medical Center
Current Research and Scholarly Interests Our research focuses on the investigation of the brain’s innate immune response, and the role that maladaptive microglial activity plays in initiation and progression of neurological disease.
Ann M. Arvin
Vice Provost and Dean of Research, Lucile Salter Packard Professor of Pediatrics and Professor of Microbiology and Immunology
Current Research and Scholarly Interests Our laboratory investigates the pathogenesis of varicella zoster virus (VZV) infection, focusing on the functional roles of particular viral gene products in pathogenesis and virus-cell interactions in differentiated human cells in humans and in Scid-hu mouse models of VZV cell tropisms in vivo, and the immunobiology of VZV infections.
Assistant Professor of Genetics
Current Research and Scholarly Interests We are interested in the mechanism by which bacterial toxins, viruses, and protein aggregates hijack the secretory pathway and kill cells. More broadly, we investigate how diverse stresses (biological, chemical) signal to the apoptotic machinery.
To pursue these interests, we develop widely applicable new technologies to screen and measure genetic interactions; these include high-complexity shRNA libraries, which have allowed the first systematic genetic interaction maps in mammalian cells.
Associate Professor of Developmental Biology, of Computer Science and of Pediatrics (Genetics)
Current Research and Scholarly Interests Dr. Bejerano, co-discoverer of ultraconserved elements, studies the Human Genome. His research focuses on genome sequence and function in both humans and related primate, mammalian and vertebrate species. He is deeply interested in mapping both coding and non-coding genome sequence variation to phenotype differences, and in extracting specific genetic insights from high throughput sequencing measurements, in the contexts of development and developmental abnormalities.
Assistant Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)
Bio Dr. Bernert is Founding Director of the Suicide Prevention Research Laboratory, within the Stanford Mood Disorders Center. She is a suicidologist, with subspecialty expertise in suicide prevention clinical trials, standardized suicide risk assessment and best practice management. She has subspecialty training in behavioral sleep medicine, with a background in sleep and circadian physiology. Her program utilizes cognitive, biologic (e.g., fMRI), and behavioral testing paradigms, with an emphasis on translational therapeutics. Dr. Bernert has collaborated with NIH, DOD, DARPA, SAMHSA, and CDC on suicide prevention initiatives; and recently served as a content expert for the 2015 Open Data and Innovation for Suicide Prevention #Hackathon, sponsored by the White House Office of Science and Technology. She has also contributed to the development of clinical practice parameters, including the 2013 VA/DOD Clinical Practice Guidelines for the Assessment and Management of Suicide Risk. Her research focuses on the identification of novel therapeutic targets for suicide prevention across the lifespan, particularly those aiming to reduce stigma and enhance access to care. A specific focus of this work emphasizes the use of rapid-action, low-risk treatment approaches for the prevention of suicide. Dr. Bernert has several suicide prevention trials underway, funded by NIH and DOD, testing the preliminary efficacy of a non pharmacological insomnia treatment on suicidal behaviors. Our aim is to delineate transdiagnostic risk factors and biomarkers of clinical response that may inform the pathogenesis of risk and treatment innovation. An overarching mission is to harness new technologies within suicide prevention, including artificial intelligence (AI) and mobile health applications, to enhance risk detection and multidisciplinary frameworks. Advisory and advocacy work, and the way in which research guides health policy, dissemination, and national strategies for suicide prevention, represents an extension of this work. This includes recent initiatives to establish guidelines for lethal means restriction and calls for advanced technology use in suicide prevention research and strategy.